Vaxcyte (FRA:5VA) Short-Term Capital Lease Obligation : €6.63 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Short-Term Capital Lease Obligation?

Vaxcyte's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €6.63 Mil.

Vaxcyte's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (€5.65 Mil) to Dec. 2023 (€6.52 Mil) and increased from Dec. 2023 (€6.52 Mil) to Mar. 2024 (€6.63 Mil).

Vaxcyte's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€4.67 Mil) to Dec. 2022 (€5.58 Mil) and increased from Dec. 2022 (€5.58 Mil) to Dec. 2023 (€6.52 Mil).

Vaxcyte Short-Term Capital Lease Obligation Historical Data

The historical data trend for Vaxcyte's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Short-Term Capital Lease Obligation Chart

Vaxcyte Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.15

4.67

5.58

6.52

Vaxcyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															5.55	5.53	5.65	6.52	6.63

Vaxcyte Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Vaxcyte Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxcyte (FRA:5VA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (FRA:5VA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PCVX:USA

Address

825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070

Website

https://www.vaxcyte.com

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.

Vaxcyte (FRA:5VA) Headlines

No Headlines